Eli Lilly and Company

Alumis Announces Upsized $259M Series C Financing to Advance Clinical-stage Pipeline of Oral Therapies Designed to Address Immune Dysfunction

Retrieved on: 
星期三, 三月 6, 2024

SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Alumis Inc., a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to transform the lives of patients with immune-mediated diseases, today announced an upsized $259M Series C financing. Alumis plans to use the proceeds of the financing to initiate pivotal Phase 3 clinical trials for its lead candidate ESK-001, a highly selective and potentially best-in-class allosteric tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe plaque psoriasis in the second half of 2024, as well as support the two ongoing Phase 2 clinical trials for ESK-001 in systemic lupus erythematosus (SLE), and non-infectious uveitis. The financing will also support the further advancement of Alumis’ precision data analytics and multi-platform approach to explore ESK-001’s potential application in other autoimmune indications, as well as A-005, a TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases, and its earlier-stage internal pipeline programs.

Key Points: 
  • Srinivas Akkaraju, M.D., Ph.D., Founder and Managing General Partner of Samsara BioCapital, and Richard Gaster, M.D., Ph.D., Managing Partner at venBio Partners, will join Alumis’ Board of Directors.
  • “This investment will support the continued clinical development of ESK-001, building on promising data that have demonstrated full, sustained target inhibition leading to a potentially best-in-class oral TYK2 inhibitor profile.
  • We are now starting to see how this will translate into outcomes for patients.
  • We are proud of the company’s progress and happy to continue to support and work with the Alumis team and Board of Directors in this next stage of the company’s growth.”

Kidney Month: 31 Day of Action to Equip and Empower People to Fight Kidney Disease

Retrieved on: 
星期四, 二月 29, 2024

During Kidney Month, AKF calls on members of the kidney community and the general public to join in solidarity in support of everyone affected by kidney disease.

Key Points: 
  • During Kidney Month, AKF calls on members of the kidney community and the general public to join in solidarity in support of everyone affected by kidney disease.
  • One of the hallmarks of Kidney Month at AKF is Kidney Action Week , which will be held March 18-22.
  • This free, virtual event will bring together patients, nephrologists, renal dieticians, caregivers and other kidney experts for a weeklong series of sessions about a variety of topics related to kidney disease, including dialysis, kidney disease prevention, kidney-friendly eating, transplant, innovations in kidney disease and more.
  • In addition, people with kidney disease have a higher chance of developing other health problems, such as heart disease.

Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update

Retrieved on: 
星期三, 二月 28, 2024

Merus also continues to evaluate patients with untreated advanced PD-L1+ HNSCC treated with petosemtamab 1500 mg in combination with pembrolizumab.

Key Points: 
  • Merus also continues to evaluate patients with untreated advanced PD-L1+ HNSCC treated with petosemtamab 1500 mg in combination with pembrolizumab.
  • Merus plans to report initial interim efficacy and safety data from this cohort in the second quarter of 2024.
  • Merus achieved a milestone and received a payment of $2.5 million related to the advancement of this program in the third quarter of 2023.
  • Merus also achieved an additional milestone of $1 million for candidate nomination in the fourth quarter of 2023.

Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
星期二, 二月 27, 2024

BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today reported pipeline updates and financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today reported pipeline updates and financial results for the fourth quarter and year ended December 31, 2023.
  • “2023 was a momentous year for Verve as we made significant strides towards our mission of protecting the world from cardiovascular disease.
  • Verve expects to initiate the VERVE-201 Phase 1b clinical trial in the second half of 2024, subject to regulatory clearances.
  • In October 2023 , Verve announced the expansion of its relationship with Lilly, which was previously established in June 2023.

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
星期二, 二月 27, 2024

Aclaris reported positive results from its Phase 1 MAD trial of ATI-2138 in September 2023.

Key Points: 
  • Aclaris reported positive results from its Phase 1 MAD trial of ATI-2138 in September 2023.
  • Net loss was $1.5 million for the fourth quarter of 2023 compared to $27.6 million for the fourth quarter of 2022.
  • Total revenue was $17.6 million for the fourth quarter of 2023 compared to $7.8 million for the fourth quarter of 2022.
  • Licensing expenses were $5.7 million for the quarter ended December 31, 2023 compared to $0.6 million for the prior year period.

GlobalData report highlights staggering economic costs for Illinois of $17.6 billion due to obesity

Retrieved on: 
星期三, 三月 6, 2024

GlobalData’s report, ‘ Obesity’s Impact on Illinois' Economy and Labor Force ,’ analyzes the economic and workforce implications of obesity in the State of Illinois, as well as the impact on state tax revenue collections and costs.

Key Points: 
  • GlobalData’s report, ‘ Obesity’s Impact on Illinois' Economy and Labor Force ,’ analyzes the economic and workforce implications of obesity in the State of Illinois, as well as the impact on state tax revenue collections and costs.
  • In Illinois, approximately one-third of adults are classified as having obesity (33.4%), and another third have overweight (33.9%) in 2022.
  • Employers in Illinois paid an extra $2.1 billion in higher medical expenditures for health complications attributed to obesity and overweight.
  • The federal government also spent an estimated $3.7 billion more on Medicare and Medicaid for Illinois residents.

GlobalData report highlights staggering $425.5 billion economic costs of obesity and overweight to U.S. Businesses and Employees in 2023

Retrieved on: 
星期四, 二月 22, 2024

Obesity and overweight are estimated to have caused a staggering $425.5 billion in economic costs to U.S. businesses and employees in 2023, according to a report released by GlobalData Plc , a leading data and analytics company.

Key Points: 
  • Obesity and overweight are estimated to have caused a staggering $425.5 billion in economic costs to U.S. businesses and employees in 2023, according to a report released by GlobalData Plc , a leading data and analytics company.
  • Of the 158 million civilian employees on nonfarm payrolls, 30% (46.9M) are classified as having obesity and 34% (53.8M) have overweight.
  • Costs amounted to $347.5 billion attributed to obesity and $78 billion attributed to overweight.
  • Costs include $146.5 billion in higher medical costs for employees and their dependents, $82.3 billion in higher absenteeism (missed workdays), $160.3 billion in higher presenteeism (reduced productivity due to illness), $31.1 billion in higher disability costs, and $5.2 billion in higher Workers’ Compensation Program costs.

Synthekine Appoints Geoff Nosrati, Ph.D., as Chief Business Officer and Announces Executive Leadership Changes

Retrieved on: 
星期三, 二月 21, 2024

Synthekine Inc ., an engineered cytokine therapeutics company, today announced the appointment of Geoff Nosrati, Ph.D., as chief business officer.

Key Points: 
  • Synthekine Inc ., an engineered cytokine therapeutics company, today announced the appointment of Geoff Nosrati, Ph.D., as chief business officer.
  • The company also announced additional changes in the executive leadership team, with Martin Oft, M.D., assuming the role of chief scientific officer and Greg Yedinak promoted to chief technical officer.
  • “Geoff is an accomplished biotechnology executive with extensive knowledge in corporate strategy and business development,” said Debanjan Ray, chief executive officer of Synthekine.
  • In his previous experience, he also served as chief business officer of ImmunoScape and held multiple senior executive roles at Aduro Biotech.

Bravo Group bolsters lobbying practice with the addition of State Street Advisors

Retrieved on: 
星期四, 三月 7, 2024

HARRISBURG, Pa., March 7, 2024 /PRNewswire/ -- Dick Hayden and Jeff Sharp - principals at State Street Advisors (SSA) - have joined Bravo Group's government relations team, adding to the practice of professionals known for their depth of public policy knowledge and relationships critical to successful representation.

Key Points: 
  • "Adding State Street Advisors is a perfect complement to our practice's unrivaled expertise in the sectors that impact people's lives," said Dennis Walsh, president of Bravo Government Relations.
  • "We have had such long-standing professional relationships with many of the folks at Bravo that the move is just a natural fit," Sharp said.
  • A former Democratic state representative from Philadelphia, Hayden expands Bravo's relationships with state and local government in Southeastern Pennsylvania.
  • Founded in 1999, Bravo Group is a strategic communications firm operating at the intersection of public affairs and marketing serving clients who make progress in people's lives.

Lilly's Newest Phase of Get Better Campaign Challenges Misperceptions About Obesity Care

Retrieved on: 
星期四, 三月 7, 2024

INDIANAPOLIS, March 7, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today launched the next phase of its Get Better corporate branding campaign with a new focus on obesity. Earlier this year, Lilly launched Get Better to reinforce its commitment to discovering and making medicines that give people a chance at better health.

Key Points: 
  • INDIANAPOLIS, March 7, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today launched the next phase of its Get Better corporate branding campaign with a new focus on obesity.
  • Earlier this year, Lilly launched Get Better to reinforce its commitment to discovering and making medicines that give people a chance at better health.
  • As a continuation of the larger campaign, Lilly will air two films - Shame and Big Night .
  • Shame, unveiled during Obesity Care Week, is designed to increase the dialogue about obesity as a serious disease and reinforce that there is no place for shame in the conversation around it.